Lung Cancer Management最新文献

{"title":"First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice.","authors":"Filip Kohutek,&nbsp;Miroslava Stratena,&nbsp;Andrej Rosik,&nbsp;Maria Tamasova,&nbsp;Branislav Bystricky","doi":"10.2217/lmt-2016-0011","DOIUrl":"https://doi.org/10.2217/lmt-2016-0011","url":null,"abstract":"<p><p>We present results of retrospective real-life data of nonsquamous lung cancer patients treated in first-line (platinum-based chemotherapy with gemcitabine without bevacizumab). 56 patients with satisfactory performance status for cytotoxic chemotherapy were treated in 2010-2014. Median progression-free survival was 6.48 months (95% CI: 4.44-9.48), time to progression was 10.19 months (95% CI: 7.59-12.19). Median overall survival was 10.8 months (95% CI: 6.72-14.52). Although our group of patients had higher proportion of elderly patients with somewhat limited performance status, progression-free survival rate was comparable to large registration studies. Overall survival, despite intervening comorbidities and subsequent limited use of second-line treatment was analogous to large gemcitabine/platinum Phase III studies in nonsquamous population. We believe our data represent real-life survival rates of unselected patients with advanced NSCLC of nonsquamous type from mostly rural catchment area.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 3","pages":"123-130"},"PeriodicalIF":2.8,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36854071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting EGFR and ALK in NSCLC: current evidence and future perspective.","authors":"Chiara Bennati, Luca Paglialunga, Biagio Ricciuti, Giulio Metro, Luca Marcomigni, Alessio Gili, Lucio Crinò","doi":"10.2217/lmt-2016-0005","DOIUrl":"10.2217/lmt-2016-0005","url":null,"abstract":"<p><p>The advent of molecular therapy targeting specific driver oncogenes has dramatically changed the prognosis of a subset of NSCLC, dilating survival and improving the quality of life of patients with advanced disease. Two of the major targets for treatment with receptor TKIs are the activated mutated forms of the <i>EGFR</i> and the <i>ALK</i> gene fusions. In advanced NSCLC patients harboring <i>EGFR</i> mutations or <i>ALK</i> rearrangements, the use of TKIs in the first-line setting, have provided unexpected large progression-free survival and overall survival benefits, compared with cytotoxic chemotherapy. However, despite initial responses and durable remissions, the development of resistance inevitably leads to treatment failure. The aim of this review is to discuss the treatment strategy currently used for tumors harboring these two genetic targets and to focus on what will be available in clinical practice in the near future.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"79-90"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310340/pdf/lmt-05-79.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36864617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptom burden in lung cancer: management updates.","authors":"Rebecca H Lehto","doi":"10.2217/lmt-2016-0001","DOIUrl":"10.2217/lmt-2016-0001","url":null,"abstract":"<p><p>Lung cancer is recognized to carry a high symptom burden with associated lowered quality of life as compared with other cancers. Research has shown that symptom severity can be a prognostic indicator of poorer clinical outcomes and survival post treatment. The purpose of this paper is to review current literature relative to symptom burden associated with diagnosis, medical and/or surgical intervention, assessment and management updates, and emerging initiatives that promote positive outcomes based on updated evidence. Discussion relative to interdisciplinary coordination of supportive services and palliative care initiation is provided.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"61-78"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310300/pdf/lmt-05-61.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36864616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy and NSCLC.","authors":"Domenico Trombetta,&nbsp;Angelo Sparaneo,&nbsp;Federico Pio Fabrizio,&nbsp;Lucia Anna Muscarella","doi":"10.2217/lmt-2016-0006","DOIUrl":"https://doi.org/10.2217/lmt-2016-0006","url":null,"abstract":"<p><p>In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance. Blood-based liquid biopsy as circulating tumor cells, circulating tumor DNA and exosomes can offer a fast and non-invasive method to elucidate the genetic heterogeneity of patients, the screening and patient stratification and give a dynamic surveillance for tumor progression and monitor treatments response. Here we prospectively discuss the three main approaches in the blood-biopsy field of lung cancer patients and its clinical applications in patient management. We also outline some of the analytical challenges that remain for liquid biopsy techniques in demonstrating that it could represent a true and actionable picture in lung cancer management for the implementation into clinical routine.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"91-104"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36864620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphnodal micrometastases in NSCLC: where do we stand?","authors":"Andrea Viti,&nbsp;Alberto Terzi,&nbsp;Giuseppe Bogina,&nbsp;Luca Bertolaccini","doi":"10.2217/lmt-2016-0009","DOIUrl":"https://doi.org/10.2217/lmt-2016-0009","url":null,"abstract":"Thoracic Surgery Unit, Sacro Cuore Don Calabria Research Hospital – Cancer Care Center, Via Don Angelo Sempreboni 5, 37024, Negrar Verona, Italy Pathology Service, Sacro Cuore Don Calabria Research Hospital – Cancer Care Center, Negrar Verona, Italy *Author for correspondence: vitimassa@hotmail.it","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"53-55"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36865117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent results of immunotherapy and perspectives for advanced NSCLC.","authors":"Denis L Jardim,&nbsp;Debora de Melo Gagliato","doi":"10.2217/lmt-2016-0007","DOIUrl":"https://doi.org/10.2217/lmt-2016-0007","url":null,"abstract":"Centro de Oncologia do Paraná – Oncoville, Curitiba, Brazil *Author for correspondence: Tel.: +55 41 3083 0988; denisjardim@centrodeoncologia.com It is estimated that 224,390 new cases of lung cancer will be diagnosed in 2016 in USA, making it the second most incident cancer for all genders, only behind breast cancer. Additionally, lung cancer will be first cause of cancer death in USA during this year, causing 150,080 estimated deaths [1]. Although lung cancer mortality is slowly decreasing over the last years, data indicate of lung cancer diagnosis and treatment is still an unmet need. One of the key challenges is that approximately 70% of lung cancers are diagnosed in advanced stage, for which curative treatment is not possible [2]. The majority (85%) of lung cancers are classified as NSCLC, while the reaming represents small-cell lung cancers, which is associated with a dismal prognosis [3]. The standard treatment for advanced NSCLC over the last decade is chemotherapy, including platinum-based doublets. These regimens are associated with a response rate (RR) of approximately 20%, and median overall survival (OS) under 12 months [4]. For selected patients, after four to six cycles of platinum-doublets regimens, maintenance therapy either with chemotherapy or EGFR inhibitors is associated with a modest improvement in OS [5]. One of the greatest advances obtained over the last decade for the management of advanced NSCLC is the consolidation of a molecular-based approach. Approximately 70% of NSCLC are nonsquamous, and 40% of them may present with a targetable genetic alteration. Tyrosine kinase inhibitors are available for patients whose tumors harbor EGFR mutations, ALK translocations and, more recently, ROS1 fusions. A matched targeted therapy is associated with an RR of 60–70%, and disease control that frequently surpasses 12 months [6]. Nonetheless, these therapies are not curative; treatment resistance development is almost a rule. In addition, there are no molecularly oriented therapies approved for advanced lung cancers with squamous cell histology. Second-line options for advanced NSCLC were restricted to docetaxel and pemetrexed.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"57-60"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36865121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review.","authors":"David Heigener,&nbsp;Thomas Küchler","doi":"10.2217/lmt-2016-0010","DOIUrl":"https://doi.org/10.2217/lmt-2016-0010","url":null,"abstract":"<p><p>Quality of life (QoL) is important to cancer patients and is increasingly included as a trial end point. The methodologies/findings of randomized controlled trials evaluating the efficacy and safety of second-line treatments approved for use in the EU in patients with advanced/metastatic NSCLC, without known targetable mutations, were evaluated. Seven trials were identified; five compared active treatments and two compared active treatment to placebo. Methodologies used and reporting varied. The European Organization for Research and Treatment of Cancer lung cancer questionnaire was the most commonly used assessment method (n = 4). There was no evidence to suggest differences in QoL between active treatments. Consistent and appropriate use of standard QoL instruments in future would increase the reliability of results and their applicability to clinical decision-making.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 2","pages":"105-116"},"PeriodicalIF":2.8,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36864619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature.","authors":"Vanita Noronha,&nbsp;Amit Joshi,&nbsp;Vijay M Patil,&nbsp;Sunny Jandyal,&nbsp;Neha Mittal,&nbsp;Nilendu Purandare,&nbsp;Jaiprakash Agarwal,&nbsp;Nandkumar Kadam,&nbsp;Kumar Prabhash","doi":"10.2217/lmt-2016-0002","DOIUrl":"https://doi.org/10.2217/lmt-2016-0002","url":null,"abstract":"<p><p>Untreated NSCLC patients with brain metastases have a median survival of approximately 2 months; locally advanced stage III NSCLC patients treated with chemoradiation have a median survival of 16-19 months. Select patients with oligometastatic disease may have a prolonged survival if managed aggressively. We present the case of a 47-year-old woman with lung adenocarcinoma, cT2aN3M1a, (supraclavicular lymph node, solitary brain metastasis). She underwent brain metastasectomy, whole brain radiation, induction chemotherapy and concurrent chemoradiotherapy. She relapsed in the brain and locoregionally and was treated with brain re-irradiation, and systemic chemotherapy. Her progression-free survival was 32 months and she is alive with recurrent disease 63 months after diagnosis. Systemic therapy is an important tool in the multimodality management of patients with oligometastatic disease.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 1","pages":"21-27"},"PeriodicalIF":2.8,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36865123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer.","authors":"Luis E Raez,&nbsp;Christian Rolfo","doi":"10.2217/lmt-2016-0003","DOIUrl":"https://doi.org/10.2217/lmt-2016-0003","url":null,"abstract":"2517 (2015). 12 Patel MR, Bauer TM, Liu SV et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33(Suppl.), Abstract 2596 (2015). 13 Burris HA, Brose MS, Shaw AT et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J. Clin. Oncol. 33(Suppl.), Abstract TPS2624 (2015). 14 TRK inhibitor shows early promise. Cancer Discov. doi:10.1158/2159-8290.CDNB2015-165 (2015) (Epub ahead of print).","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 1","pages":"1-4"},"PeriodicalIF":2.8,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36865114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nintedanib in advanced NSCLC: management of adverse events.","authors":"Liesbeth Lemmens","doi":"10.2217/lmt.15.33","DOIUrl":"10.2217/lmt.15.33","url":null,"abstract":"<p><p>Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patients. The most frequent adverse events (AEs) associated with nintedanib are gastrointestinal events and elevations in liver enzymes. Most AEs can be managed effectively with supportive treatment or a dose reduction and do not require permanent discontinuation. This article aims to provide practical guidance on management of AEs and how patients should be assessed for AEs prior to initiation and regularly monitored throughout treatment. Patients and their carers can play an important role in recognizing and managing AEs and should be given the relevant information, skills and confidence to achieve this.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 1","pages":"29-41"},"PeriodicalIF":2.8,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt.15.33","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36865118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}